NASDAQ:MESO Mesoblast Q4 2026 Earnings Report $15.13 +0.26 (+1.75%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$15.12 -0.01 (-0.07%) As of 09/18/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Mesoblast EPS ResultsActual EPS-$0.07Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMesoblast Revenue ResultsActual Revenue$34.45 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMesoblast Announcement DetailsQuarterQ4 2026Date7/31/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Mesoblast Earnings HeadlinesWhy brokers see 85% upside for this ASX biotech stockSeptember 4, 2026 | msn.comExperts tip these $3 billion ASX shares to deliver over 75% returnsSeptember 1, 2026 | msn.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | Decentralized Masters (Ad)Mesoblast Limited (MESO) Q4 2026 Earnings Call TranscriptAugust 27, 2026 | seekingalpha.comMesoblast Reports Substantial Revenue Growth to US$120MAugust 26, 2026 | globenewswire.comMesoblast earnings: Strong revenue growth and operational milestones in FY26August 26, 2026 | msn.comSee More Mesoblast Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mesoblast? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mesoblast and other key companies, straight to your email. Email Address About MesoblastMesoblast (NASDAQ:MESO) (NASDAQ: MESO) is a biotechnology company focused on developing and commercializing regenerative medicine products based on proprietary mesenchymal lineage stromal cells. The company’s cell therapies are designed to address serious inflammatory and immune-mediated conditions by potentially reducing inflammation, supporting tissue repair and modulating immune responses. Mesoblast’s lead product, remestemcel-L, is marketed in the United States as Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. The therapy received approval from the U.S. Food and Drug Administration in 2024 and is the company’s first commercial product in the United States. Mesoblast has also investigated cell-based therapies for conditions including chronic heart failure, chronic low back pain and other inflammatory disorders. Founded in 2004 and headquartered in Melbourne, Australia, Mesoblast has conducted research and clinical development activities in the United States, Australia and other international markets. The company’s products and candidates have been developed through internal research programs and collaborations with pharmaceutical and healthcare organizations. Mesoblast is led by founder and Chief Executive Officer Silviu Itescu, who has overseen the company’s development of allogeneic cellular medicines.View Mesoblast ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
